TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE18.7900
- TODAY'S CHANGE (%)0.4800 (2.6215%)
- Bid / Lots18.4000/ 1
- Ask / Lots18.9000/ 5
- Open / Previous Close18.4980 / 18.3100
- Day Range
- 52 Week Range
- Volume1,207,218
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 23020 | 18.345 |
| 09:34 ET | 3387 | 18.3801 |
| 09:36 ET | 3222 | 18.31 |
| 09:38 ET | 2100 | 18.3 |
| 09:39 ET | 5246 | 18.21 |
| 09:41 ET | 6478 | 18.28 |
| 09:43 ET | 2100 | 18.31 |
| 09:45 ET | 600 | 18.245 |
| 09:48 ET | 2200 | 18.27 |
| 09:50 ET | 3203 | 18.26 |
| 09:52 ET | 4119 | 18.285 |
| 09:54 ET | 1500 | 18.22 |
| 09:56 ET | 7671 | 18.245 |
| 09:57 ET | 1586 | 18.265 |
| 09:59 ET | 2101 | 18.29 |
| 10:01 ET | 4354 | 18.3233 |
| 10:03 ET | 3332 | 18.27 |
| 10:06 ET | 3800 | 18.26 |
| 10:08 ET | 3018 | 18.35 |
| 10:10 ET | 10633 | 18.385 |
| 10:12 ET | 8878 | 18.52 |
| 10:14 ET | 26956 | 18.63 |
| 10:15 ET | 65604 | 18.89 |
| 10:17 ET | 67655 | 19.035 |
| 10:19 ET | 26509 | 19.05 |
| 10:21 ET | 31998 | 18.985 |
| 10:24 ET | 23259 | 18.89 |
| 10:26 ET | 7517 | 18.83 |
| 10:28 ET | 6342 | 18.87 |
| 10:30 ET | 12824 | 18.9 |
| 10:32 ET | 8797 | 18.92 |
| 10:33 ET | 4605 | 18.94 |
| 10:35 ET | 5907 | 18.99 |
| 10:37 ET | 15921 | 18.892 |
| 10:39 ET | 17051 | 18.821 |
| 10:42 ET | 5429 | 18.83 |
| 10:44 ET | 9976 | 18.77 |
| 10:46 ET | 5182 | 18.75 |
| 10:48 ET | 11002 | 18.72 |
| 10:50 ET | 14338 | 18.77 |
| 10:51 ET | 5459 | 18.75 |
| 10:53 ET | 2576 | 18.75 |
| 10:55 ET | 2808 | 18.75 |
| 10:57 ET | 2024 | 18.76 |
| 11:00 ET | 6968 | 18.74 |
| 11:02 ET | 2059 | 18.755 |
| 11:04 ET | 5782 | 18.76 |
| 11:06 ET | 1327 | 18.76 |
| 11:08 ET | 12861 | 18.74 |
| 11:09 ET | 8715 | 18.8 |
| 11:11 ET | 8437 | 18.7908 |
| 11:13 ET | 4863 | 18.83 |
| 11:15 ET | 3524 | 18.815 |
| 11:18 ET | 7632 | 18.83 |
| 11:20 ET | 3659 | 18.875 |
| 11:22 ET | 7914 | 18.86 |
| 11:24 ET | 2535 | 18.86 |
| 11:26 ET | 1528 | 18.86 |
| 11:27 ET | 45370 | 18.86 |
| 11:29 ET | 5812 | 18.83 |
| 11:31 ET | 2662 | 18.8 |
| 11:33 ET | 3260 | 18.7756 |
| 11:36 ET | 6329 | 18.85 |
| 11:38 ET | 1050 | 18.8476 |
| 11:40 ET | 8472 | 18.78 |
| 11:42 ET | 2686 | 18.78 |
| 11:44 ET | 6310 | 18.765 |
| 11:45 ET | 4578 | 18.76 |
| 11:47 ET | 15933 | 18.805 |
| 11:49 ET | 3819 | 18.78 |
| 11:51 ET | 9255 | 18.77 |
| 11:54 ET | 1408 | 18.77 |
| 11:56 ET | 300 | 18.78 |
| 11:58 ET | 5652 | 18.825 |
| 12:00 ET | 2859 | 18.8 |
| 12:02 ET | 1799 | 18.79 |
| 12:03 ET | 2168 | 18.805 |
| 12:05 ET | 4896 | 18.827 |
| 12:07 ET | 1231 | 18.84 |
| 12:09 ET | 1753 | 18.84 |
| 12:12 ET | 5603 | 18.8499 |
| 12:14 ET | 2721 | 18.83 |
| 12:16 ET | 819 | 18.835 |
| 12:18 ET | 5696 | 18.76 |
| 12:20 ET | 7955 | 18.68 |
| 12:21 ET | 3199 | 18.7 |
| 12:23 ET | 10848 | 18.64 |
| 12:25 ET | 5415 | 18.69 |
| 12:27 ET | 4560 | 18.65 |
| 12:30 ET | 5473 | 18.66 |
| 12:32 ET | 16249 | 18.729 |
| 12:34 ET | 9897 | 18.68 |
| 12:36 ET | 9629 | 18.69 |
| 12:38 ET | 6162 | 18.629 |
| 12:39 ET | 5568 | 18.609 |
| 12:41 ET | 13767 | 18.59 |
| 12:43 ET | 7893 | 18.59 |
| 12:45 ET | 4825 | 18.5505 |
| 12:48 ET | 2763 | 18.61 |
| 12:50 ET | 5260 | 18.6246 |
| 12:52 ET | 3969 | 18.61 |
| 12:54 ET | 24975 | 18.71 |
| 12:56 ET | 6509 | 18.73 |
| 12:57 ET | 18998 | 18.76 |
| 12:59 ET | 57796 | 18.79 |
Jun 11, 2024
Jun 7, 2024
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:50AM ET on Friday Jun 07, 2024 by Dow Jones
7:50AM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 2.9B | 85.2x | --- |
Twist Bioscience Corp | 2.8B | -14.3x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.9x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
ADMA Biologics Inc | 2.6B | -549.5x | --- |
Denali Therapeutics Inc | 3.0B | -22.0x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 85.2x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | 70.2x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
